Premium
The roles of PD ‐1/ PD ‐L1 and its signalling pathway in gastrointestinal tract cancers
Author(s) -
Cui Chunguo,
Yu Bo,
Jiang Qi,
Li Xingfang,
Shi Kaiyao,
Yang Zecheng
Publication year - 2019
Publication title -
clinical and experimental pharmacology and physiology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.752
H-Index - 103
eISSN - 1440-1681
pISSN - 0305-1870
DOI - 10.1111/1440-1681.13028
Subject(s) - immunotherapy , blockade , gastrointestinal tract , cancer , immune system , medicine , cancer immunotherapy , pd l1 , cancer research , gastrointestinal cancer , colorectal cancer , immune checkpoint , immunology , receptor
Summary Cancer immunotherapy has been increasingly applied in the treatment of advanced malignancies. Consequently, immune checkpoints have become a major concern. As PD ‐1 is an important immunomodulatory protein, the blockade of PD ‐1 and its ligand PD ‐L1 is a promising tumour immunotherapy for human carcinoma. In this review, we first discuss the role of the PD ‐1/ PD ‐L1 interaction in gastrointestinal tract cancers. Targeting PD ‐1 and PD ‐L1 in immune cells and tumour cells may show remarkable efficiency in gastrointestinal tract cancers. Second, the PD ‐1/ PD ‐L1‐associated signalling pathway involved in cancer immunotherapy in gastrointestinal tract cancers is discussed. Most importantly, this review summarizes the PD ‐1/ PD ‐L1‐targeted immunotherapy combinations with relevant signalling pathways, which may result in a breakthrough for the treatment of gastrointestinal tract cancers, such as gastric cancer, colorectal cancer and liver cancer. Meanwhile, the review provides a deeper insight into the mechanism of checkpoint blockade immunotherapies.